Oxford Genome Sciences (UK) Ltd has announced that it has licensed its OGAP® database to UCB.
Oxford Genome Anatomy Project (OGAP) integrates clinical, proteomic, and genomic information to accelerate the discovery and validation of drug targets and biomarkers in man.
The benefits are improved biomarkers for patient selection, drug response and efficacy monitoring, and the integration of diagnostics into drug development and product launch, thereby facilitating accurate drug development.
Oxford claims that, OGAP holds the world’s largest proprietary collection of proteins represented by the database, which contains over one million peptide sequences from 50 tissues and 60 disease states, mapped to approximately 16,000 genes and over eight million SNPs.
The database can be customised for individual partners to support and enhance their preclinical and clinical drug development activities.
“We’re delighted that UCB has decided to capitalise on the potential of our OGAP database to enhance their drug discovery efforts,” said Dr. Christian Rohlff, CEO of OGeS.
“With the pharmaceutical focus on using biomarkers to accelerate drug development, data integration is a key technology for translational medicine and integrated molecular approaches to targeted therapies and personalised medicine.”
“The database is an invaluable source of information to accelerate the development of clinical biomarkers and diagnostics.”
“OGAP is a good example how IT convergence brings genomics, SNP and proteomics together, improving the information we need to support discovery,” explained Dr. John Bouck, Head of R&D Informatics at UCB.
“This collaboration is a further step in the implementation of UCB’s strategy to co-operate with external partners to exploit existing, innovative knowledge for our development pipeline.”